Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00162279 · ClinicalTrials.gov registry record · Phase 2

The Study of Abatacept in Combination With Etanercept

A Phase 2 study of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
141
Enrollment target
20
Study locations

NCT00162279 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 141 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00162279, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
141 participants
Enrollment target
20
Study locations

Study Summary

The Study was designed to look at the safety and efficacy of abatacept in combination with etanercept.

Conditions Studied

Interventions

  • DRUG Abatacept

Study Locations (20)

California

  • Local Institution - La Jolla
  • Local Institution - Long Beach
  • Local Institution - Los Angeles
  • Local Institution - Palo Alto
  • Local Institution - San Francisco

Florida

  • Local Institution - Fort Lauderdale
  • Local Institution - Titusville

Massachusetts

  • Local Institution - Boston
  • Local Institution - Springfield

New York

  • Local Institution - Albany
  • Local Institution - Mineola

Alabama

  • Local Institution - Huntsville

Colorado

  • Local Institution - Denver

Georgia

  • Local Institution - Rome

Illinois

  • Local Institution - Chicago

Trial Details

FieldValue
Enrollment Target 141 participants
Start Date 2000-10
Est. Completion 2007-02
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT00162279

The ClinicalTrials.gov registry entry for NCT00162279 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Abatacept is the first listed.

NCT00162279 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00162279 about?

NCT00162279 is a clinical study titled "The Study of Abatacept in Combination With Etanercept". The Study was designed to look at the safety and efficacy of abatacept in combination with etanercept.

What is the current status of trial NCT00162279?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2000-10. Estimated completion is 2007-02.

What conditions does trial NCT00162279 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT00162279?

The interventions under investigation include: Abatacept (DRUG).

Who is sponsoring clinical trial NCT00162279?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00162279 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.